The Clinical Management Guidelines for Friedreich Ataxia have been updated and relaunched in November 2022.

The Clinical Management Guidelines for Friedreich Ataxia in its entirety is the collective work of many authors including practitioners, researchers, patients and caregivers. Though it is grounded in research, we also acknowledge the importance of honoring the real life experiences of those who have been impacted by this disease and are grateful for their contribution.

These Guidelines are made available as general information only and do not constitute medical advice. These Guidelines are intended to assist qualified healthcare professionals make informed treatment decisions about the care of individuals with Friedreich ataxia. They are not intended as a sole source of guidance in managing issues related to Friedreich ataxia. Rather, they are designed to assist clinicians by providing an evidence-based framework for decision-making.

These Guidelines are not intended to replace clinical judgment and other approaches to diagnosing and managing problems associated with Friedreich ataxia which may be appropriate in specific circumstances. Ultimately, healthcare professionals must make their own treatment decisions on a case-by-case basis, after consultation with their patients, using their clinical judgment, knowledge and expertise.

See below link for the Clinical Management Guidelines for Friedreich Ataxia.